Illness script · Toxicology

Serotonin Syndrome

Life-threatening excess serotonergic activity at CNS/PNS receptors, classically from drug combination, causing neuromuscular, autonomic, and mental status changes.

This illness script for Serotonin Syndrome covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.

Updated Jul 19, 2026All scripts

01

Predisposing factors

  • Most common trigger: SSRI + another serotonergic agent (tramadol, linezolid, triptans, fentanyl, MDMA, dextromethorphan)
  • MAOIs carry highest risk — especially combined with SSRIs or meperidine
  • Recreational drug use (MDMA, cocaine) is a common precipitant in young patients
  • Therapeutic dosing errors or intentional overdose with serotonergic drugs
  • Any new serotonergic drug addition increases risk even at standard doses

02

Presentation

  • Classic triad: altered mental status + autonomic instability + neuromuscular abnormalities
  • Clonus (inducible, spontaneous, or ocular) is the most specific finding
  • Hyperreflexia and clonus GREATER in lower extremities than upper — key exam pearl
  • Autonomic features: hyperthermia, tachycardia, diaphoresis, hypertension, mydriasis
  • Onset rapid: usually <24 hours (often within 6 hours) of offending agent
  • Severe cases: hyperthermia >41°C, rhabdomyolysis, seizures, cardiovascular collapse

03

Pathophysiology

  • Excess stimulation of 5-HT1A and 5-HT2A receptors in brainstem and spinal cord
  • 5-HT2A activation → neuromuscular hyperactivity (clonus, rigidity) and autonomic instability
  • Spinal cord interneuron hyperexcitability drives clonus, the hallmark finding
  • Onset typically within minutes to hours of drug exposure or dose change

04

Diagnostics

  • Clinical diagnosis using Hunter Criteria (most sensitive/specific; no lab required)
  • Hunter Criteria: serotonergic drug + clonus, agitation, diaphoresis, tremor, hyperreflexia combinations
  • No specific serum serotonin level is diagnostic or clinically useful
  • Workup to assess severity: CK (rhabdomyolysis), BMP (renal function, electrolytes), CBC
  • ECG to evaluate QTc; lactate if hemodynamically unstable

05

Management

  • Immediately discontinue ALL serotonergic agents
  • Benzodiazepines (first-line) for agitation, neuromuscular hyperactivity, and seizures
  • Cyproheptadine (5-HT2A antagonist) — antidote; give orally or via NG tube
  • Aggressive cooling for hyperthermia >41°C; avoid antipyretics (not prostaglandin-mediated)
  • ICU admission for severe cases; avoid succinylcholine (hyperkalemia risk with rigidity); avoid physical restraints alone
  • Symptoms typically resolve within 24 hours once offending agents stopped

06

Clinical pivots

How to separate this script from the look-alikes that show up on exams and on the wards.

  • Neuroleptic Malignant Syndrome

    NMS: onset over days–weeks with bradykinesia/lead-pipe rigidity, NOT clonus/hyperreflexia; caused by dopamine antagonists not serotonergic drugs

  • Anticholinergic Toxidrome

    Anticholinergic: hot/dry/flushed skin, urinary retention, absent bowel sounds; NO clonus or diaphoresis

  • Malignant Hyperthermia

    MH: triggered by inhaled anesthetics or succinylcholine intraoperatively; muscle rigidity with masseter spasm; RYR1 mutation

  • Sympathomimetic Toxidrome

    Sympathomimetic: shares tachycardia/hypertension/hyperthermia but lacks clonus and hyperreflexia; no serotonergic drug exposure

View full library

Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.